A transdermal drug delivery system for delivering a therapeutically effective amount of drug over an extended period of time, wherein the drug is selected from the group consisting of amphetamine, d-amphetamine, l-amphetamine, d,l-amphetamine, methaphetamine, prilocaine, benzocaine, butacaine, butamben, butanilicaine, corticaine, lidocaine, memantine, pilocarpine/Cyclobenzaprine, paroxetine, fluoxetine, duloxetine, imipramine, dedpramine, doxeprin, nortriptylene, protriptylene, bupropion, azelastine, chlorphenamine, bisoprolol, pheniramine, alprazolam, captopril, clonidine, clonazepam, enalapril, ramipril, haloperidol, ketoprofen, loratadine, methimazole, methylphenidate, methyl testosterone, nicotine, nitroglycerin, pramipexole, ropinirole, hydromorphone, scopolamine, testosterone, estradiol, methamphetamine, frovatriptan and phentermine and wherein the transdermal drug delivery system comprises: (a) a carrier composition comprising (i) a pressure sensitive adhesive including at least one acrylic-based polymer and present in an amount from 5% to 97% by weight of said transdermal drug delivery system and (ii) 0.1% to about 50% by weight of at least one drug for transdermal drug delivery, and (b) an occlusive backing layer, wherein said occlusive backing layer is formed of a plurality of layers wherein a first layer of said backing layer is formed of polyester and a second layer of said backing layer is formed of polyurethane, and wherein the occlusive backing layer has a moisture vapor transmission rate of from about 0.5 to about 1500 g/m 2 /24 hrs measured at 40 °C and 90% relative humidity that is selected to selectively control the transdermal permeation of said drug from said transdermal drug delivery system to achieve extended drug delivery over at least seven days. wherein the drug is selected from the group consisting of amphetamine, d-amphetamine, l-amphetamine, d,l-amphetamine, methaphetamine, prilocaine, benzocaine, butacaine, butamben, butanilicaine, corticaine, lidocaine, memantine, pilocarpine/Cyclobenzaprine, paroxetine, fluoxetine, duloxetine, imipramine, dedpramine, doxeprin, nortriptylene, protriptylene, bupropion, azelastine, chlorphenamine, bisoprolol, pheniramine, alprazolam, captopril, clonidine, clonazepam, enalapril, ramipril, haloperidol, ketoprofen, loratadine, methimazole, methylphenidate, methyl testosterone, nicotine, nitroglycerin, pramipexole, ropinirole, hydromorphone, scopolamine, testosterone, estradiol, methamphetamine, frovatriptan and phentermine and wherein the transdermal drug delivery system comprises: (a) a carrier composition comprising (i) a pressure sensitive adhesive including at least one acrylic-based polymer and present in an amount from 5% to 97% by weight of said transdermal drug delivery system and (ii) 0.1% to about 50% by weight of at least one drug for transdermal drug delivery, and (b) an occlusive backing layer, wherein said occlusive backing layer is formed of a plurality of layers wherein a first layer of said backing layer is formed of polyester and a second layer of said backing layer is formed of polyurethane, and wherein the occlusive backing layer has a moisture vapor transmission rate of from about 0.5 to about 1500 g/m 2 /24 hrs measured at 40 °C and 90% relative humidity that is selected to selectively control the transdermal permeation of said drug from said transdermal drug delivery system to achieve extended drug delivery over at least seven days. (a) a carrier composition comprising (i) a pressure sensitive adhesive including at least one acrylic-based polymer and present in an amount from 5% to 97% by weight of said transdermal drug delivery system and (ii) 0.1% to about 50% by weight of at least one drug for transdermal drug delivery, and (b) an occlusive backing layer, wherein said occlusive backing layer is formed of a plurality of layers wherein a first layer of said backing layer is formed of polyester and a second layer of said backing layer is formed of polyurethane, and wherein the occlusive backing layer has a moisture vapor transmission rate of from about 0.5 to about 1500 g/m 2 /24 hrs measured at 40 °C and 90% relative humidity that is selected to selectively control the transdermal permeation of said drug from said transdermal drug delivery system to achieve extended drug delivery over at least seven days.